---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-215674"
form_type: "8-K"
ticker: "LXEO"
cik: "0001907108"
company_name: "Lexeo Therapeutics, Inc."
filed_at: "2026-05-11T23:59:59+00:00"
generated_at: "2026-05-14T19:00:25.526124+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Lexeo Therapeutics Q1 net loss $20.2M; cash $227.6M; LX2006 pivotal trial protocol submitted to FDA

## Summary
- Net loss $20.2M ($0.25/share) vs $32.7M ($0.99) in Q1 2025; R&D $15.7M, G&A $6.6M.
- Cash, equivalents & investments $227.6M at March 31, 2026; expected runway into 2028.
- LX2006 SUNRISE-FA2 pivotal protocol and SAP submitted to FDA; initiation expected Q2 2026.
- Appointed Laura Sepp-Lorenzino, Ph.D., former CSO of Intellia, to Board of Directors.
- ASGCT presentations: LX2006 shows significant mFARS improvement vs natural history (p=0.003); LX2022 preclinical data.

## SEC filing metadata
- accession: 0001193125-26-215674
- form_type: 8-K
- ticker: LXEO
- cik: 0001907108
- company_name: Lexeo Therapeutics, Inc.
- filed_at: 2026-05-11T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1907108/000119312526215674/0001193125-26-215674-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1907108/000119312526215674/lxeo-20260511.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-215674
- JSON: https://secwatch.observer/filing/0001193125-26-215674.json
- Plain text: https://secwatch.observer/filing/0001193125-26-215674.txt

## Source-grounded claims
- claim_id: c0dec8379e317f2ca7512f0e23718151b78bfbab
  claim: Lexeo Therapeutics, Inc. reported the first quarter 2026 results: net income Net loss was $20.2 million or $0.25 per share (basic and diluted) for the three months ended March 31, 2026, EPS $0.25 per share (basic and diluted).
  evidence_excerpt: Lexeo Therapeutics Reports First Quarter 2026 Financial Results and Operational Highlights
  evidence_url: https://www.sec.gov/Archives/edgar/data/1907108/000119312526215674/0001193125-26-215674-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.